Bone Marrow Transplantation最新文献_第4页

Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT. 欧洲及相关国家造血细胞移植和细胞治疗技术的利用情况。利用 2022 年活动调查数据与经济和人口因素相关联。EBMT 的报告。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-22 DOI: 10.1038/s41409-024-02459-0

Jakob R Passweg, Helen Baldomero, Tobias Alexander, Emanuele Angelucci, Dina Averbuch, Ali Bazarbachi, Fabio Ciceri, Greco Raffaella, Mette D Hazenberg, Krzysztof Kalwak, Donal P McLornan, Antonio M Risitano, Annalisa Ruggeri, John A Snowden, Anna Sureda

{"title":"Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT.","authors":"Jakob R Passweg, Helen Baldomero, Tobias Alexander, Emanuele Angelucci, Dina Averbuch, Ali Bazarbachi, Fabio Ciceri, Greco Raffaella, Mette D Hazenberg, Krzysztof Kalwak, Donal P McLornan, Antonio M Risitano, Annalisa Ruggeri, John A Snowden, Anna Sureda","doi":"10.1038/s41409-024-02459-0","DOIUrl":"https://doi.org/10.1038/s41409-024-02459-0","url":null,"abstract":"We looked at treatment rates and center density across countries for patients treated in 2022; 46,143 HCTs (19,011 (41.2%) allogeneic, 27,132 (58.8%) autologous) reported by 689 centers. 4329 patients received advanced cellular therapies, 3205 were CAR-T. We found considerable differences in utilization of autologous, allogeneic HCT and more so for CAR-T. Differences in procedure type and for allogeneic HCT in donor use and disease indication are highlighted. For instance, countries with the highest use of unrelated donors per 10 million inhabitants were Germany (297) and the Netherlands (230), for identical sibling HCT it was Israel (148) and Lebanon (113), for haploidentical it was Israel (94) and Italy (94) and for cord blood it was the Netherlands (24) and the United Kingdom (15). We looked at HCT use for specific indications in allogeneic HCT (AML CR1, MDS, MPN and BMF). We correlated treatment rates with GNI and with demographic age structure and show correlations in HCT and CAR-T use and center density, highest in Italy for allogeneic and autologous HCT and in Switzerland for CAR-T. Resource restricted countries tend to concentrate HCT use in a limited number of centers. These data are useful for comparisons across countries.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience. BLIND研究：采用blinatumomab和DLI方法治疗异基因干细胞移植后B-ALL复发。意大利多中心经验。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-21 DOI: 10.1038/s41409-024-02475-0

S Giammarco, R Maggi, Luca Di Marino, P Chiusolo, L Teofili, N Piccirilo, E Metafuni, M A Limongiello, S Leotta, G Milone, A Cupri, I Cutini, R Saccardi, C Nozzoli, R Boncompagni, A Gozzini, B Scappini, M Piccini, N S Fracchiolla, S Sica

引用次数: 0

Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice. 急性髓细胞性白血病的可测量残留疾病检测和异基因造血细胞移植：将 Pre-MEASURE 应用于临床实践。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-20 DOI: 10.1038/s41409-024-02481-2

Brian C Shaffer, Partow Kebriaei, Marcos de Lima, Antonio M Jimenez Jimenez

{"title":"Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice.","authors":"Brian C Shaffer, Partow Kebriaei, Marcos de Lima, Antonio M Jimenez Jimenez","doi":"10.1038/s41409-024-02481-2","DOIUrl":"https://doi.org/10.1038/s41409-024-02481-2","url":null,"abstract":"Measurable residual disease (MRD) testing in patients with acute myelogenous leukemia (AML) represents a heterogenous assessment process designed to quantify leukemia-specific biomarkers that are not ascertainable by routine pathologic evaluation. The most common tools used to assess MRD are multiparameter flow cytometry (MPFC), and polymerase chain reaction (PCR) based tools, including quantitative or digital droplet PCR (qPCR, ddPCR), or next-generation sequencing (NGS) technologies. Collectively, MRD assessments have become an important clinical tool in the management of patients with AML. Despite progress, significant questions remain with respect to the appropriate timing, frequency, and methodology of MRD assessment, and whether or how to adapt therapy based on MRD results. Recent data from the Pre-MEASURE study, a retrospective cohort analysis of error corrected NGS based MRD assessment prior to allogeneic hematopoietic cell transplantation (alloHCT) in patients with AML, provides additional key information with respect to the emerging role of NGS-based technology in MRD assessment. In the context of this review, we evaluate the Pre-MEASURE study as well as other recent, high-quality assessments of MRD in AML. Our focus is to provide a practical assessment of the use of emerging MRD technologies in patients with AML with an emphasis on the role of peri-transplant MRD for the practicing clinician.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA. 达拉单抗在异基因造血干细胞移植后并发症中的作用：一项关于PRCA和AIHA的单中心前瞻性研究。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-20 DOI: 10.1038/s41409-024-02479-w

S Giammarco, M A Limongiello, Luca Di Marino, Elisabetta Metafuni, Luciana Teofili, Patrizia Chiusolo, Simona Sica

{"title":"The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA.","authors":"S Giammarco, M A Limongiello, Luca Di Marino, Elisabetta Metafuni, Luciana Teofili, Patrizia Chiusolo, Simona Sica","doi":"10.1038/s41409-024-02479-w","DOIUrl":"https://doi.org/10.1038/s41409-024-02479-w","url":null,"abstract":"Pure red cell aplasia (PRCA) and autoimmune hemolytic anemia (AIHA) post-hematopoietic stem cell transplantation (HSCT) are an unmet medical need with no established standard of care, significantly affecting the patient quality of life and posing a challenge for clinicians. The anti-CD38 IgG-kappa Daratumumab appears to be a safe and efficace treatment compared to prior drugs. Our study is a prospective monocentric investigation assessing the use of daratumumab in these complications following allo-HSCT. Here we describe our experience on six patients with a median age of 65 years. All treated patients, except one, who died because of sepsis during GVHD exacerbation, reached transfusion independence with erythropoietin suspension. Poor graft function remains a management challenge for clinicians and has a significant impact on the patient's quality of life. Currently, therapeutic options for PRCA and for the least common AIHA, appear ineffective, making it difficult to address the diverse needs of post-transplant patients. Although our data and those previously reported in the literature are preliminary, daratumumab prompts further reflection on its use in this setting of patients.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142680394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study. 孤立性玻璃体视网膜淋巴瘤患者的大剂量化疗与自体造血干细胞移植：LOC网络研究。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-19 DOI: 10.1038/s41409-024-02477-y

Adam Mainguy, Carole Soussain, Valérie Touitou, Amin Bennedjai, Laurent Kodjikian, Hervé Ghesquières, Gandhi Damaj, Rémy Gressin, Jean-Baptiste Ducloyer, Olivier Chinot, Anaïs Vautier, Cécile Moluçon-Chabrot, Guido Ahle, Luc Taillandier, Jean Pierre Marolleau, Adrien Chauchet, Fabrice Jardin, Nathalie Cassoux, Denis Malaise, Adélaïde Toutée, Sara Touhami, Magali Le Garff-Tavernier, Khê Hoang-Xuan, Sylvain Choquet, Caroline Houillier

{"title":"High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.","authors":"Adam Mainguy, Carole Soussain, Valérie Touitou, Amin Bennedjai, Laurent Kodjikian, Hervé Ghesquières, Gandhi Damaj, Rémy Gressin, Jean-Baptiste Ducloyer, Olivier Chinot, Anaïs Vautier, Cécile Moluçon-Chabrot, Guido Ahle, Luc Taillandier, Jean Pierre Marolleau, Adrien Chauchet, Fabrice Jardin, Nathalie Cassoux, Denis Malaise, Adélaïde Toutée, Sara Touhami, Magali Le Garff-Tavernier, Khê Hoang-Xuan, Sylvain Choquet, Caroline Houillier","doi":"10.1038/s41409-024-02477-y","DOIUrl":"https://doi.org/10.1038/s41409-024-02477-y","url":null,"abstract":"Despite its indolent evolution, vitreoretinal lymphoma (VRL) has a poor prognosis due to a major risk of relapse in the central nervous system (CNS) and may necessitate aggressive therapy. However, the use of high-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) is poorly documented. We retrospectively analysed from the French LOC network database the adult immunocompetent patients treated with HCT-ASCT for isolated VRL. Thirty-eight patients underwent consolidation with HCT-ASCT for isolated VRL between 2008 and 2019 after induction chemotherapy. Twenty patients had primary VRL, and 18 had an isolated VRL relapse of a primary CNS lymphoma. Three patients underwent HCT-ASCT in first-line treatment, 24 in second-line treatment, and 11 in subsequent lines. At HCT-ASCT, the median age was 61 years, and the median KPS was 90. Thirty-two patients (84%) received high-dose thiotepa-based HCT. One patient (3%) died from HCT-ASCT toxicity. Nineteen (50%) patients relapsed after HCT-ASCT, including 17 cases occurring in the brain. The median progression-free survival, brain-free survival and overall survival from HCT-ASCT were 96, 113 and 92 months, respectively. HCT-ASCT represents an effective therapeutic strategy for select VRL patients, with a tolerable safety profile. However, the risk of subsequent brain relapse remains significant.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis. 异体器官移植后的免疫重建和感染--移植后环磷酰胺、ATLG和非ATLG预防GvHD的比较。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-19 DOI: 10.1038/s41409-024-02474-1

Thomas Meyer, Kristina Maas-Bauer, Ralph Wäsch, Justus Duyster, Robert Zeiser, Jürgen Finke, Claudia Wehr

{"title":"Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis.","authors":"Thomas Meyer, Kristina Maas-Bauer, Ralph Wäsch, Justus Duyster, Robert Zeiser, Jürgen Finke, Claudia Wehr","doi":"10.1038/s41409-024-02474-1","DOIUrl":"https://doi.org/10.1038/s41409-024-02474-1","url":null,"abstract":"Immunological reconstitution after allogeneic hematopoietic cell transplantation (alloHCT) is critical for patient survival. We compared short- and long-term immune reconstitution and clinical endpoints in adult recipients of haploidentical or mismatched T cell replete peripheral blood stem cell transplants (PBSCT) with post-transplant cyclophosphamide as GvHD prophylaxis (PTCY, n = 68) to: (a) patients receiving matched unrelated grafts and anti-T lymphocyte globulin (ATLG) (MUD/ATLG, n = 280); (b) patients with a mismatched donor and ATLG (MM/ATLG, n = 54); and (c) recipients of matched related grafts without ATLG (MRD/NoATLG, n = 97). PTCY was associated with delayed neutrophil engraftment, low NK-cell counts on day 30 and reduced CD8+ cells on days 60-80. In terms of long-term reconstitution, PTCY recipients demonstrated significantly higher CD4+ counts from day 100-365, primarily derived from naïve T cells. Additionally, B-lymphocyte counts at one year were highest in the PTCY group. Early morbidity and mortality due to infectious complications (viral reactivation, (blood stream) infections) were most frequent in PTCY patients during the first three months. However, beyond three months, no PTCY patient suffered a fatal infection. Our study highlights the pattern of early immunodeficiency followed by robust long-term immune reconstitution in PTCY recipients, identifying critical time periods of risk that could be targeted to optimise patient survival and reduce infectious complications.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice. 贝卢莫司地联合疗法在实际临床实践中治疗慢性移植物抗宿主病。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-18 DOI: 10.1038/s41409-024-02476-z

Michelle M Chin, John S Tamaresis, Laura J Johnston, Robert Lowsky, Everett Meyer, Lori Muffly, Parveen Shiraz, Matthew J Frank, Andrew R Rezvani, Sushma Bharadwaj, Wen-Kai Weng, Judith A Shizuru, Sally Arai

引用次数: 0

Successful allogeneic CD34⁺ hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC). B细胞急性淋巴细胞白血病患者接受CAR T细胞疗法后，成功通过异体CD34+造血干细胞增殖治疗缓解长期细胞减少症。代表西班牙造血移植和细胞疗法小组（GETH-TC）。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-17 DOI: 10.1038/s41409-024-02473-2

Águeda Molinos-Quintana, Nuria Martínez-Cibrian, Anna Alonso-Saladrigues, Víctor Galán-Gómez, Rebeca Bailén, Susana Buendía-López, Carolina Fuentes-Socorro, Mi Kwon, Marta González-Vincent, Concepción Pérez de Soto, Berta González-Martínez, Susana Rives, José María Pérez-Hurtado, Valentín Ortiz-Maldonado, José Antonio Pérez-Simón

引用次数: 0

Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study. 急性髓细胞性白血病患者异基因干细胞移植后MRD阳性的移植前风险因素：一项前瞻性研究。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-16 DOI: 10.1038/s41409-024-02466-1

Si-Qi Li, Chun-Zi Yu, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Yu-Qian Sun, Chen-Hua Yan, Meng Lv, Xiao-Dong Mo, Yan-Rong Liu, Kai-Yan Liu, Xiao-Su Zhao, Xiang-Yu Zhao, Xiao-Jun Huang, Ying-Jun Chang

{"title":"Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.","authors":"Si-Qi Li, Chun-Zi Yu, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Yu-Qian Sun, Chen-Hua Yan, Meng Lv, Xiao-Dong Mo, Yan-Rong Liu, Kai-Yan Liu, Xiao-Su Zhao, Xiang-Yu Zhao, Xiao-Jun Huang, Ying-Jun Chang","doi":"10.1038/s41409-024-02466-1","DOIUrl":"https://doi.org/10.1038/s41409-024-02466-1","url":null,"abstract":"We aimed to prospectively explore the risk factors for measurable residual disease (MRD) positivity after allogeneic stem cell transplantation (allo-SCT) in AML patients (n = 478). The cumulative incidences (CIs) of post-SCT MRD positivity at 100 days, 360 days and 3 years were 4.6%, 12.1% and 18.3%, respectively. Positive pre-SCT MRD and pre-SCT active disease were risk factors for post-SCT MRD positivity at both 360 days and 3 years (P < 0.001). European LeukemiaNet (ELN) 2017 risk stratification was a risk factor for positive post-SCT MRD at 360 days (P = 0.044). A scoring system for predicting post-SCT MRD positivity at 360 days was established by using pre-SCT MRD, pre-SCT active disease and ELN 2017 risk stratification. The CI of positive post-SCT MRD at 3 years was 13.2%, 23.7%, and 43.9% for patients with scores of 0, 1, and 2, respectively (P < 0.001). Multivariate analysis demonstrated that the scoring system was associated with a higher CI of post-SCT MRD positivity, leukemia relapse and inferior survival. Our data indicate that positive pre-SCT MRD status, pre-SCT active disease, and ELN 2017 risk stratification are risk factors for positive post-SCT MRD status in AML patients.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma. 用移植后环磷酰胺加依维莫司预防难治性T细胞和B细胞淋巴瘤的GvHD。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-15 DOI: 10.1038/s41409-024-02472-3

Tim Richardson, Hishan Tharmaseelan, Lukas Frenzel, Philipp Gödel, Moritz Fürstenau, Pascal Nieper, Till Braun, Daniel Schütte, Michael Hallek, Christof Scheid, Udo Holtick

引用次数: 0